Antidepressants do not broadly weaken the immune system in the way that, say, chemotherapy drugs or organ-transplant immunosuppressants do. What they do is reshape how the immune system behaves, dialing down some inflammatory responses while leaving other defenses intact or even boosting them. The relationship is more complicated than a simple on-off switch, and the net effect often depends on which antidepressant you take, what your immune system looked like before you started, and whether depression itself had already thrown your immunity off balance.
Depression Itself Changes Your Immune System
Before asking what antidepressants do to immune function, it helps to know what depression does. People with untreated major depression tend to have elevated levels of pro-inflammatory signaling molecules in their blood. A meta-analysis of drug-naïve patients found that circulating levels of tumor necrosis factor-alpha (TNF-α), one of the body’s key inflammation drivers, were significantly higher in depressed individuals than in healthy controls.1PubMed Central. Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis Other inflammatory markers like interleukin-6 and C-reactive protein also run high in depression. Even adolescents experiencing their first depressive episode show shifts in inflammatory and anti-inflammatory cytokine balance compared to healthy peers.2PubMed Central. The relationship between serum resolvin D1, NLRP3, cytokine levels, and adolescents with first-episode medication-naïve major depressive disorder
Untreated depression also disrupts cortisol regulation. Depressed patients who are not on medication show higher daytime cortisol levels and greater resistance to the normal cortisol feedback loop compared to both medicated patients and healthy people.3PubMed Central. Childhood trauma, HPA axis activity and antidepressant response in patients with depression Chronically elevated cortisol suppresses parts of the immune system while simultaneously stoking the kind of low-grade inflammation linked to heart disease, diabetes, and other chronic conditions. So the starting point for someone considering antidepressants is rarely a healthy immune baseline. The immune system is already running hot and dysregulated.
How Antidepressants Change Inflammatory Markers
The most consistent finding across studies is that antidepressant treatment brings elevated inflammatory markers back down toward normal levels. After a course of treatment, serum levels of inflammatory cytokines and high-sensitivity C-reactive protein drop significantly in depressed patients.4PubMed. The change of inflammatory cytokines after antidepressant treatment and correlation with depressive symptoms In one study, eight weeks of treatment with either venlafaxine or paroxetine brought interleukin-1β levels down to the range seen in healthy individuals.5PubMed Central. Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)
If you think of the immune system as having a “volume dial” for inflammation, depression cranks it up, and antidepressants turn it back down. That is not the same thing as suppressing immunity. Inflammation is only one arm of the immune response, and excessive inflammation actually makes the body worse at fighting infections, not better. A fire alarm going off constantly does not protect the building; it just means something is already wrong. By calming that alarm, antidepressants can help restore a more functional immune state.
Why Serotonin Matters to Your Immune Cells
The reason antidepressants affect the immune system at all is that serotonin is not just a brain chemical. Nearly all immune cells carry receptors for serotonin, and many immune tissues express multiple types of serotonin receptors.6PubMed. mRNA expression of serotonin receptors in cells of the immune tissues of the rat Serotonin can suppress the release of TNF-α and interleukin-1β from immune cells, influence how aggressively neutrophils are recruited to an infection site, and modulate T-cell activation.7PubMed Central. The Effects of Serotonin in Immune Cells
Because SSRIs change how much serotonin is available in the spaces between cells throughout the body, not just in the brain, they inevitably alter how immune cells communicate and respond. This is not an accidental side effect so much as a consequence of serotonin being a shared messenger between the nervous and immune systems. The immune effects are baked into the drug’s mechanism.
Effects on Specific Immune Cells
The picture gets more nuanced when you look at individual cell types. Lab studies have found that SSRIs like paroxetine and sertraline can reduce T-cell viability and suppress their secretion of TNF-α at concentrations achievable in the body. Those studies described the inhibitory effect as even more pronounced than what dexamethasone, a standard immunosuppressive steroid, achieved.8PubMed. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression Broader reviews have confirmed that SSRIs can reduce lymphocyte proliferation, alter which cytokines immune cells secrete, and even trigger programmed cell death in some immune cells.9PubMed. Selective serotonin reuptake inhibitors as a novel class of immunosuppressants
That sounds alarming on its face, but context matters. These are in-vitro findings, meaning they come from cells in a dish, often exposed to drug concentrations at the higher end of what you would see in a living person. And the effects are selective, not wholesale destruction. SSRIs tend to dampen the overactive, inflammatory arm of the T-cell response while leaving the broader defensive machinery less affected.
Natural killer cells, which patrol for virus-infected cells and early tumors, tell a more complicated story. Older tricyclic antidepressants like imipramine and amitriptyline inhibited natural killer cell activity in lab studies.10PubMed. Tricyclic antidepressants inhibit human natural killer cells But fluoxetine (Prozac) actually boosted natural killer cell activity in depressed patients who had low activity at baseline, while having no effect in those whose activity was already normal. Fluoxetine and paroxetine also enhanced natural killer cell activity in lab experiments.11PubMed. Antidepressants augment natural killer cell activity: in vivo and in vitro In other words, the drug seemed to help people whose immune defenses were flagging while leaving those with healthy defenses alone. That pattern, where the effect depends on the starting state, comes up repeatedly in this research.
Not All Antidepressants Are the Same
One of the biggest misconceptions is treating antidepressants as a single category. The immune effects vary substantially by drug class. A systematic review comparing drug classes found that SSRIs appear to reduce levels of interleukin-6 and TNF-α, while other antidepressant types, though effective against depression, did not consistently reduce cytokine levels.12PubMed Central. Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression Evidence from clinical studies suggests nortriptyline, a tricyclic, may be more anti-inflammatory than escitalopram, an SSRI, at least in patients who start out with high inflammation.12PubMed Central. Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression
Among atypical antidepressants, the differences are even starker. Bupropion lowers circulating TNF-α, while mirtazapine raises it.13PubMed. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels That is essentially opposite immune directions from two drugs prescribed for the same condition. For someone whose depression involves a lot of physical inflammation, or who has an inflammatory medical condition alongside depression, this distinction could matter clinically. It also means blanket statements about “antidepressants and the immune system” are inherently oversimplified.
Do People on Antidepressants Get Sick More Often?
Lab studies on isolated cells are one thing. The question most people actually care about is whether taking an antidepressant will make them catch more colds, more pneumonia, or more infections generally. The epidemiological evidence here is reassuring but messy.
A large observational study comparing new users of several common antidepressants found infection rates that were roughly similar across drugs, hovering around 77 to 99 acute infections per 1,000 person-years. Fluoxetine and venlafaxine users had slightly lower infection rates compared to citalopram users, but the differences were modest and hovered near the range where they could be attributed to other factors.14PubMed. The risk of acute infections in new users of antidepressants: An observational cohort study There was no meaningful difference in COVID-19 infection rates between groups.
Pneumonia risk is a bit more complicated. A study of elderly patients with Parkinson’s disease found that current users of tricyclics and MAO inhibitors had a lower risk of pneumonia compared to non-users, while SSRI users had a modestly higher risk.15PubMed Central. Antidepressants Usage and Risk of Pneumonia Among Elderly Patients With the Parkinson’s Disease: A Population-Based Case-Control Study Before jumping to conclusions, though, an earlier study found that the apparent link between antidepressant use and pneumonia hospitalization largely disappeared once researchers accounted for the other health conditions antidepressant users tend to have. The raw association showed about 60 percent higher pneumonia risk, but after adjusting for things like other illnesses and overall health status, the association dropped to essentially zero.16PubMed Central. Observed Association between Antidepressant Use and Pneumonia Risk Was Confounded by Comorbidity Measures Depression itself carries health burdens that increase infection susceptibility, including disrupted sleep, poor nutrition, reduced physical activity, and the chronic inflammation described earlier. Untangling the drug’s effect from the disease’s effect is genuinely difficult.
Antidepressants and Brain Inflammation
A parallel line of research has looked at microglia, the resident immune cells of the brain. When microglia become chronically activated, they drive neuroinflammation, a process linked to depression itself and to neurodegenerative diseases. A systematic review found that SSRIs, SNRIs, MAO inhibitors, and tricyclics all prevented microglial activation, reducing both immune signaling and oxidative stress products in experimental models.17PubMed Central. Modulation of microglial activation by antidepressants A meta-analysis of preclinical studies confirmed strong evidence that antidepressants dampen microglial activation, but only when those cells are already in an activated, inflamed state. In models without existing activation, antidepressants had no effect on inflammatory markers.18Journal of Affective Disorders Reports. Antidepressants as a potential candidate to reduce microglia activation in neurodegenerative diseases. A systematic review and meta-analysis of preclinical studies
That pattern echoes what was seen with natural killer cells: antidepressants tend to correct immune dysfunction rather than suppress healthy immunity. They bring overactive systems back toward baseline without pushing balanced systems into suppression. Researchers have noted this could mean antidepressants have therapeutic potential in diseases where brain inflammation plays a causal role, independent of their effects on mood.
Antidepressants and Autoimmune Conditions
If antidepressants are broadly anti-inflammatory, you might expect them to help in autoimmune diseases, where the immune system attacks the body’s own tissues. The evidence here is preliminary but intriguing. Case reports have documented patients with Crohn’s disease achieving long-lasting remission while taking antidepressants. Phenelzine (an MAO inhibitor) and bupropion both led to sustained remission in individual patients, and researchers proposed this was tied to the drugs’ ability to lower TNF-α, a molecule that plays a central role in Crohn’s disease.19PubMed Central. Antidepressants and inflammatory bowel disease: a systematic review
A larger observational study of inflammatory bowel disease patients painted a more ambiguous picture. Antidepressant use was associated with more corticosteroid prescriptions, more hospitalizations, and more emergency visits, but not with more disease-specific complications or surgeries. Antidepressant users actually had a lower rate of IBD-associated surgery.20Scientific Reports. Clinical outcomes associated with antidepressant use in inflammatory bowel disease patients and a matched control cohort The higher hospitalization rate likely reflects the fact that IBD patients who also have depression are sicker overall, not that the antidepressant is making the bowel disease worse. Still, the relationship between antidepressants and autoimmune conditions remains one of those areas where clinicians and researchers are watching closely but do not have enough controlled data to make strong recommendations.
The Fluvoxamine and COVID-19 Episode
During the pandemic, the SSRI fluvoxamine attracted attention as a potential treatment for COVID-19. The interest was grounded in fluvoxamine’s activity at the sigma-1 receptor, which can suppress the kind of runaway cytokine production that makes severe COVID-19 deadly.21PubMed Central. Old drug fluvoxamine, new hope for COVID-19 SSRIs have also been studied for potential antimicrobial and immunomodulatory effects that could affect the interaction between the gut microbiome and the immune system.22PubMed Central. The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds
The fluvoxamine story is worth knowing because it illustrates a broader point: the same anti-inflammatory properties that sound scary when framed as “immunosuppression” can look like a lifeline when the problem is an overactive immune response. In severe COVID-19, the virus itself does less damage than the immune system’s overreaction to it. An antidepressant that calms that overreaction is not weakening immunity. It is redirecting it away from self-harm. Whether fluvoxamine ultimately proves clinically useful for infections is still being investigated, but the premise, that taming inflammation can be protective, is well established.
Vaccine Response and Antidepressants
One practical concern for people on antidepressants is whether the drugs could blunt the immune response to vaccines. A population-based study in Catalonia looked at antibody levels after COVID-19 vaccination among people with various psychiatric conditions and found that participants on second-generation antipsychotics and those on multiple classes of psychiatric drugs had lower antibody levels. Antidepressants alone were not singled out as a driver of reduced antibody responses in that study, though the research is still sparse enough that definitive claims are premature. For now, there is no clinical recommendation to delay or modify vaccination for people taking antidepressants, and the theoretical concern has not translated into documented problems with vaccine effectiveness in this population.
Why “Immunosuppressant” Is the Wrong Word
Some research papers use the word “immunosuppressant” to describe SSRIs, and that terminology has leaked into online discussions in a way that creates real anxiety. The problem is that immunosuppression in the clinical sense means drugs like cyclosporine or methotrexate, which broadly and powerfully shut down immune function, leaving patients vulnerable to opportunistic infections and requiring regular blood monitoring. Antidepressants do nothing like that. They modulate specific immune signaling pathways, primarily dampening inflammatory responses that are already running higher than they should be. Calling that immunosuppression is technically defensible in a narrow laboratory context and profoundly misleading in a doctor’s-office context.
The distinction matters for anyone weighing the decision to start or continue an antidepressant. If you are worried that taking sertraline will make you catch every cold that goes around the office, the evidence does not support that fear. If anything, leaving depression untreated is more likely to compromise your immune function than treating it with medication, because chronic depression raises inflammation, disrupts cortisol regulation, degrades sleep, and reduces the physical activity that supports immune health.
When the Immune Effects Might Actually Matter
There are situations where the immune-modulating properties of antidepressants warrant real attention. If you have an autoimmune condition, the choice of antidepressant could matter, given that bupropion and mirtazapine push TNF-α in opposite directions. If you are an elderly patient with Parkinson’s disease, the modest pneumonia risk differences between drug classes could factor into treatment decisions.15PubMed Central. Antidepressants Usage and Risk of Pneumonia Among Elderly Patients With the Parkinson’s Disease: A Population-Based Case-Control Study If you are undergoing cancer treatment, the effect of tricyclics on natural killer cell activity versus the boosting effect of fluoxetine could be a conversation worth having with your oncologist.
For most people prescribed an antidepressant for depression or anxiety, though, the immune effects are a background feature of the drug, not a reason to avoid it. The anti-inflammatory shift that antidepressants produce is, in the majority of cases, corrective rather than harmful. It moves a dysregulated system closer to where it should be. That is not weakness. That is the immune system getting back to doing its actual job instead of fighting shadows.